Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company is going to participate in Motilal Oswal Annual Global Investor Conference scheduled on September 14 and 15, 202114-09-2021
14-09-2021
Zydus Cadila gets USFDA nod for schizophrenia treatment drug
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Brexpiprazole tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, the drug firm said in a statement.09-09-2021
Zydus Cadila gets USFDA's approval to market diabetes medication
Drug firm Zydus Cadila on Monday said it has received approval from the US health regulator to market Sitagliptin, a medicine indicated to treat diabetes.06-09-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila's Sitagliptin base tablets receives Tentative Approval from FDA06-09-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the investor call arranged on August 23, 2021 to discuss about the receipt of Emergency Use Authorization of ZyCoV-D vaccine03-09-2021
Cadila Healthcare Ltd - 532321 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India02-09-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate02-09-2021
Biological E gets DCGI approval to conduct phase 2/3 trials on children
The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI.The trial will be conducted in ten locations.The permission has been given to Biological E after the recommendation from the Subject Expert Committee.Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are underway, and its result is expected in September.It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.02-09-2021
LIC acquires over 6.64 lakh shares of Cadila Healthcare, takes stake to above 5%
The insurance company said it acquired 6,64,104 shares of Cadila Healthcare, amounting to an additional stake of 0.065 per cent in the company.01-09-2021